Warning Letter 738238 is dated September 18, 2026 and addressed to Empower Clinic Services, LLC dba Empower Pharmacy, Houston, Texas. The FDA's warning-letter database lists it as posted September 22, 2026 under the subject "CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug" (database search, read Nov 18, 2026). It follows an inspection "From November 3, 2025, through November 14, 2025," a Form FDA 483 issued November 14, 2025, and firm responses dated December 8, 2025, March 18, 2026 and April 30, 2026.
The products it names, in the letter's own strings:
| Product as written in the letter | Vial | Concentration | Active drug per vial (arithmetic) |
| SEMAGLUTIDE/CYANOCOBALAMIN | 1 mL | 5/0.5 mg/mL | 5 mg semaglutide, 0.5 mg cyanocobalamin |
| TIRZEPATIDE/NIACINAMIDE | 2.5 mL | 8/2 mg/mL | 20 mg tirzepatide, 5 mg niacinamide |
| TIRZEPATIDE/NIACINAMIDE | 4 mL | 17/2 mg/mL | 68 mg tirzepatide, 8 mg niacinamide |
Source: Warning Letter 738238, September 18, 2026, read Nov 18, 2026. Per-vial figures are mg/mL multiplied by mL. They are not doses and not weeks of supply; see our page on reading a compounded vial in mg, not units.
The core charge is under section 503A, the patient-specific compounding route. The FDA writes that these products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and that "production records collected during the inspection indicate that your firm compounded these drug products regularly or in inordinate amounts." For each of July, August, September and October 2025 the letter says the firm "compounded and filled more than (b)(4) orders" of each product; the quantities are redacted.
The sentence that matters most for anyone on a B12 or niacinamide formulation: "FDA is aware of high demand for compounded versions of FDA-approved semaglutide and tirzepatide products. The volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual."
The evidence the FDA lists is three-fold: "(1) orders/prescriptions that lack any prescriber determination of significant difference from the commercially available product; (2) orders/prescriptions with purported prescriber determinations of 'significant difference' that appear to be repeated verbatim across many records, suggesting that they may be pre-generated for selection by the prescriber, rather than written by the prescriber for an identified individual patient; and (3) the volume of particular products compounded and orders filled." It adds that such statements can arrive "through third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference." That is a description of a telehealth workflow, and it is the reason this letter reaches further than one pharmacy.
The consequence the FDA draws: products outside 503A lose the exemptions from "the FDA approval requirement of section 505," the labeling requirement of section 502(f)(1), and CGMP under 501(a)(2)(B). The letter also alleges the products were "prepared, packed, or held under insanitary conditions," citing smoke studies and media fills, and lists five CGMP violations. It states, "You do not have any FDA-approved applications on file for the ineligible drug products that you compounded." The firm had "fifteen (15) working days" to respond; the letter warns that failure to address the violations "may result in legal action without further notice, including, without limitation, seizure and injunction." As of Nov 18, 2026 the database shows no response letter and no close-out letter.
Two cautions. First, a warning letter sets out what the FDA says "appears" to violate the law; it is not a court finding. Second, none of the three provider pages we read on Nov 18, 2026 names Empower as its pharmacy, and this page does not say that any provider listed here is supplied by it.